Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

Tue, 02nd Jan 2024 07:57

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

The London Stock Exchange will reopen today after being closed for New Year's Day on Monday.

Manufacturing PMI data will be released for the UK at 0930 GMT, alongside figures for the EU and Germany in the morning, followed by US data in the afternoon.

In corporate news, AstraZeneca said that its and Sanofi's Beyfortus treatment has been approved in China, while Airtel Africa's chief executive will retire, with the firm promoting a successor from within.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.2% at 7,749.84

----------

Hang Seng: down 1.6% at 16,769.35

Nikkei 225: financial markets in Japan closed for New Year holiday

S&P/ASX 200: closed up 0.5% at 7,627.80

----------

DJIA: closed down 20.56 points, or 0.1%, at 37,689.54

S&P 500: closed down 13.52 points, or 0.3%, at 4,769.83

Nasdaq Composite: closed down 83.78 points, or 0.6%, to 15,011.35

----------

EUR: down at USD1.1033 (USD1.1074)

GBP: down at USD1.2736 (USD1.2747)

USD: up at JPY141.46 (JPY141.42)

Gold: up at USD2,074.88 per ounce (USD2,065.02)

Oil (Brent): up at USD78.29 a barrel (USD77.56)

(changes since previous London equities close)

----------

ECONOMICS

----------

Tuesday's key economic events still to come:

09:55 CET Germany manufacturing PMI

10:00 CET EU manufacturing PMI

09:30 GMT UK manufacturing PMI

09:45 EST US manufacturing PMI

----------

UK shop price inflation was unchanged at 4.3% in December, its lowest in a year and a half, but the British Retail Consortium warned that cost pressures threaten to put an end to easing inflation in 2024. The BRC-NielsenIQ shop price index was up 4.3% in December from a year before, the annual rise slower than the three-month average rate of 4.6% and the lowest since June 2022. Food price inflation slowed to 6.7% last month from 7.8% in November. Fresh food price rose by 5.4% annually in December, slowing from 6.7% the month before, while ambient food inflation slowed to 8.4% from 9.2%. However, non-food price inflation picked up to 3.1% in December from 2.5% in November.

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its and Sanofi's long-acting monoclonal antibody treatment Beyfortus has been approved in China for the prevention of respiratory syncytial virus lower respiratory tract infection in neonates and infants. The Cambridge-based pharmaceutical firm said the approval by China's National Medical Products Administration is based on three "pivotal" late-stage clinical trials and an "extensive" local clinical development programme. It is anticipated to be available during the upcoming 2024/25 RSV season. Beyfortus was approved in the EU in October 2022 and received approval by the US Food & Drug Administration in July 2023 following the unanimous recommendation by the Antimicrobial Drugs Advisory Committee in June 2023. AstraZeneca said regulatory applications are currently under review in Japan and "several other countries".

----------

Airtel Africa announced the retirement of Chief Executive Officer Segun Ogunsanya, naming Transformation Director Sunil Taldar as his successor. Taldar joined the telecommunications company in October and will be appointed to the board as CEO and executive director following a transition period at the beginning of July. At this time, Ogunsanya will formally retire but will be available to advise Chair Sunil Bharti Mittal, the board and incoming CEO Taldar for a 12-month period. Mittal said: "Under Segun's leadership, Airtel Africa has maintained double-digit revenue growth and continued to deliver new, industry-leading products to our customers across Africa...[Taldar's] industry experience, strategic vision, constant customer focus and proven record of delivery will enable him to deliver our strategic objectives and to lead the group in the next stages of its development."

----------

Outgoing BT Chief Philip Jansen has been approached about the next chair of marketing services firm WPP, according to a report from Sky News on Monday. Jansen, who is set to leave BT in the spring, is reportedly one of a number of candidates to have been considered in recent weeks for the WPP chairmanship. City sources on Monday said WPP's search was yet to reach an advanced stage and that there was no certainty that Jansen or WPP would opt to progress his candidacy further.

----------

COMPANIES - FTSE 250

----------

Balfour Beatty said it has appointed corporate brokers to manage an initial tranche of its 2024 share buyback programme, repurchasing up to GBP50 million or 63.2 million shares. The infrastructure construction firm intends for this initial tranche to be completed by the end of June, while the total anticipated 2024 share buyback will be confirmed with the firm's full year results in March.

----------

OTHER COMPANIES

----------

Zanaga said it has agreed a loan repayment extension with FTSE 100-listed mining firm Glencore to the end of March from the end of December. In June, both parties entered into a loan facility agreement, under which a loan of up to USD1.8 million would be provided to Zanaga's partially-owned subsidiary Jumelles by Glencore to provide funding for ongoing working capital required to progress initiatives at the Zanaga project. Zanaga has already paid USD463,000 of the loan facility. Zanaga Chair Clifford Elphick said: "ZIOC is pleased with the ongoing progress being made in advancing discussions with potential partners, and as part of ZIOC's strategic objectives has already recently concluded an [memorandum of understanding] relating to power solutions for the Zanaga project. We look forward to progressing further strategic initiatives in early 2024."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.